Skip to main
BLUE
BLUE logo

bluebird bio (BLUE) Stock Forecast & Price Target

bluebird bio (BLUE) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 25%
Buy 28%
Hold 41%
Sell 3%
Strong Sell 3%

Bulls say

bluebird bio Inc. is emphasizing its commitment to developing potentially curative gene therapies for severe genetic diseases, including sickle cell disease and beta-thalassemia, which may lead to significant value creation and cost reduction in healthcare. The company's alignment with ESG principles suggests a strategic focus on sustainable finance, positioning bluebird bio favorably for long-term growth in the biotechnology sector. Despite currently negative gross margins, there is potential for improvement as sales increase, particularly for treatments like SCD, which have lower cost of goods sold, indicating potential future profitability.

Bears say

bluebird bio Inc. has experienced a significant revenue decline, reporting total product revenue of $16.1 million in Q2 2024, which raises concerns about the sustainability of Zynteglo's adoption nearly two years post-launch. The company faces negative gross margins and lacks clarity on how manufacturing costs might improve with future sales, indicating potential financial distress. Additionally, the persistent net losses, amounting to $61 million in the latest quarter, alongside a missed revenue consensus, suggest challenges in achieving profitable operations in the near term.

bluebird bio (BLUE) has been analyzed by 32 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 28% recommend Buy, 41% suggest Holding, 3% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of bluebird bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About bluebird bio (BLUE) Forecast

Analysts have given bluebird bio (BLUE) a Buy based on their latest research and market trends.

According to 32 analysts, bluebird bio (BLUE) has a Buy consensus rating as of Jun 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.66, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.66, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

bluebird bio (BLUE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.